Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Goos D. Laverman
Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial
Hypertension
Internal Medicine
Related publications
The Losartan Renal Protection Study--Rationale, Study Design and Baseline Characteristics of RENAAL (Reduction of Endpoints in NIDDM With the Angiotensin II Antagonist Losartan).
JRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Internal Medicine
Endocrinology
Effect of the Angiotensin II Receptor Antagonist Losartan on Uric Acid and Oxypurine Metabolism in Healthy Subjects.
Internal Medicine
Internal Medicine
Medicine
Long-Term Effects of Angiotensin II Receptor Antagonist Losartan on Uric Acid Metabolism in Hyperuricemic Patients
Gout and Nucleic Acid Metabolism
Serum Uric Acid Is a Strong Predictor of Stroke in Patients With Non Insulin-Dependent Diabetes Mellitus
Stroke
Cardiology
Neurology
Cardiovascular Medicine
Advanced
Medicine
Neuroscience
Specialized Nursing
Clinical Usefulness of Losartan, an Angiotensin II Receptor Antagonist With a Uricosuric Effect, and the Influence of Aspirin on the Effect in Hypertensive Patients With Hyperuricemia
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
Microalbuminuria; “Comparison of Losartan Potassium and Lisinopril in Treatment of Patients With Type Ii Diabetes Mellitus”
THE PROFESSIONAL MEDICAL JOURNAL
Seasonal Dosage-Dependent Hypersensitivity to the Angiotensin II Receptor Blocker, Losartan. A Case Report and Review
Effect of Losartan, an Angiotensin II Type 1 Receptor Antagonist on Cardiac Autonomic Functions of Rats During Acute and Chronic Inhibition of Nitric Oxide Synthesis
Physiological Research
Medicine
Physiology
Letter Regarding Article by Devereux Et Al, "Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial"
Circulation
Cardiovascular Medicine
Physiology
Cardiology
